CEL-SCI extends Orient's rights to Multikine
This article was originally published in Scrip
Executive Summary
CEL-SCI has extended its licensing deal with Taiwan's Orient Europharmafor the oncology product Multikine (mixed naturally derived cytokines). The deal gives Orient exclusive rights in South Korea, the Philippines, Australia and New Zealand, in addition to Taiwan, to Multikine for head and neck, nasopharyngeal and cervical cancer. Orient will register and sell the product in these markets and will split revenues with the US firm. It has also invested $500,000 in CEL-SCI as part of the tie-up and will help fund and carry out a global 800-patient Phase III trial in head and neck squamous cell carcinoma set to start next year. CEL-SCI is seeking first-line status for Multikine in this setting, for which the US FDA has granted orphan status as a neoadjuvant therapy. Teva holds certain rights to Multikine in Israel and Turkey.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.